Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Gastroenterology | Family Medicine
Disease Category: Colorectal Cancer
Location: United States, ND
Metastatic Colorectal Cancer with wild-type KRAS tumors.
Objective response rate, duration of reponse, time to response, time to progression, disease control, overall survival, to evaluate changes in patient-reported outcomes.
Patient Inclusion Criteria:
- 18 + years
- Diagnosis of metastatic adenocarcinoma of the colon or rectum that cannot, in the opinon of the investigator, be cured by surgical resection at the time of randomization, wild-type KRAS expressing mCRC tumor, at least one uni-dimensionally measurable lesion
Patient Exclusion Criteria:
- adiotherapy <14 days before randomization, evidence of central nervous system metastases, history of other invasive primary cancer
Dr. Tom Davis, Director of Business Development
Legacy Pharma Research
601 N. 5th St.
Bismarck, ND 58501
Research Center Information: Legacy Pharma Research
If you would like to learn more about participating in this study, please send an email message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these